CN110237117A - A kind of soft capsule and preparation method thereof of Menopause anti-aging - Google Patents
A kind of soft capsule and preparation method thereof of Menopause anti-aging Download PDFInfo
- Publication number
- CN110237117A CN110237117A CN201910650635.9A CN201910650635A CN110237117A CN 110237117 A CN110237117 A CN 110237117A CN 201910650635 A CN201910650635 A CN 201910650635A CN 110237117 A CN110237117 A CN 110237117A
- Authority
- CN
- China
- Prior art keywords
- menopause
- capsule
- soft capsule
- gelatin
- aging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007901 soft capsule Substances 0.000 title claims abstract description 41
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 29
- 230000009245 menopause Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 108010010803 Gelatin Proteins 0.000 claims abstract description 29
- 239000008273 gelatin Substances 0.000 claims abstract description 29
- 229920000159 gelatin Polymers 0.000 claims abstract description 29
- 235000019322 gelatine Nutrition 0.000 claims abstract description 29
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 29
- 239000002775 capsule Substances 0.000 claims abstract description 27
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 25
- 239000003086 colorant Substances 0.000 claims abstract description 23
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims abstract description 22
- 235000008696 isoflavones Nutrition 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 150000002515 isoflavone derivatives Chemical class 0.000 claims abstract description 20
- 239000000375 suspending agent Substances 0.000 claims abstract description 19
- 239000000080 wetting agent Substances 0.000 claims abstract description 19
- 235000019220 whole milk chocolate Nutrition 0.000 claims abstract description 17
- 239000004014 plasticizer Substances 0.000 claims abstract description 15
- 239000000047 product Substances 0.000 claims abstract description 12
- 239000001058 brown pigment Substances 0.000 claims abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 8
- 239000003292 glue Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 11
- 239000011229 interlayer Substances 0.000 claims description 10
- 238000004321 preservation Methods 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000000835 fiber Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000004513 sizing Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 4
- 108090000526 Papain Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 229940055729 papain Drugs 0.000 claims description 4
- 235000019834 papain Nutrition 0.000 claims description 4
- 229940083466 soybean lecithin Drugs 0.000 claims description 4
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 3
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 238000002525 ultrasonication Methods 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 235000015110 jellies Nutrition 0.000 claims 1
- 239000008274 jelly Substances 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 208000024891 symptom Diseases 0.000 abstract description 11
- 239000003963 antioxidant agent Substances 0.000 abstract description 6
- 230000003078 antioxidant effect Effects 0.000 abstract description 6
- 235000006708 antioxidants Nutrition 0.000 abstract description 6
- 239000013589 supplement Substances 0.000 abstract description 4
- 239000011159 matrix material Substances 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229940011871 estrogen Drugs 0.000 description 8
- 239000000262 estrogen Substances 0.000 description 8
- 244000068988 Glycine max Species 0.000 description 6
- 235000010469 Glycine max Nutrition 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 241000201282 Limonium Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- CUXYLFPMQMFGPL-BGDVVUGTSA-N (9Z,11E,13Z)-octadecatrienoic acid Chemical compound CCCC\C=C/C=C/C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-BGDVVUGTSA-N 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 208000009205 Tinnitus Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 201000010251 cutis laxa Diseases 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 231100000886 tinnitus Toxicity 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- 244000025254 Cannabis sativa Species 0.000 description 3
- 206010027304 Menopausal symptoms Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- UICBCXONCUFSOI-UHFFFAOYSA-N n'-phenylacetohydrazide Chemical compound CC(=O)NNC1=CC=CC=C1 UICBCXONCUFSOI-UHFFFAOYSA-N 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000738645 Limonium aureum Species 0.000 description 2
- 241000209454 Plumbaginaceae Species 0.000 description 2
- 244000294611 Punica granatum Species 0.000 description 2
- 235000014360 Punica granatum Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- CUXYLFPMQMFGPL-UYWAGRGNSA-N trichosanic acid Natural products CCCCC=C/C=C/C=CCCCCCCCC(=O)O CUXYLFPMQMFGPL-UYWAGRGNSA-N 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001149107 Limonium bicolor Species 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010033165 Ovarian failure Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 244000007853 Sarothamnus scoparius Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000007674 genetic toxicity Effects 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000539 ovarian failure Toxicity 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of soft capsules and preparation method thereof of Menopause anti-aging, belong to health product technology field.The soft capsule is made of capsule 's content and capsule shells, the weight proportion of the capsule 's content are as follows: isoflavones extract powder: granada seed oil: twocolor sealavander herb extract: suspending agent: wetting agent=5:(85~92): (5~8): (2~8): (1~7);The capsule shells are made of gelatin, plasticizer, colorant and water;The weight ratio of the gelatin, plasticizer and water are as follows: 1:(0.3~0.7): 1;The colorant is made of antholeucin and milk chocolate brown pigment, and wherein antholeucin is the 0.05% of gelatin weight, and milk chocolate brown pigment is the 0.5% of gelatin weight.Matrix of the present invention using granada seed oil as soft capsule, in conjunction with isoflavones and twocolor sealavander herb extract, three's synergistic effect, anti-oxidant, anti-aging is not only acted as, alleviates the effect of Menopause symptom, can also significantly supplement women vim and vigour, keep women radiant, complexion is full, and skin becomes smooth flexible, the comprehensive constitution of women be improved significantly.
Description
Technical field
The present invention relates to a kind of soft capsules and preparation method thereof of Menopause anti-aging, belong to pharmaceutical preparation and health care
Product technical field.
Background technique
The study found that some variations can occur for physilogical characteristics, such as: estrogen secretion subtracts after women reaches a dating
It is few, Scavenging activity decline of interior free yl etc..These variations cause the quality of life of women to decline, and accelerate declining for women
Always, the generation of disease is even resulted in, this namely usually said Menopause.Menopausal syndrome is women premenopausal
Afterwards due to ovarian failure, decrease in estrogen, promoting sexual gland hormone raising, patient during organism endocrine is readjusted
It does not adapt to cause vegetative nerve functional disturbance, with one group of syndrome of neuropsychological symptom.Modern medical research has found that female
Property whole body have more than 400 kinds of estrogen receptor, these receptors are distributed in all tissues and organ of almost women whole body, receive female to swash
The control and domination of element will cause the degeneration variation of organ and tissue, occur one once the endocrine estrogen of body is reduced
The symptom of series.
In recent years, the treatment for being found to be menopausal syndrome of phytoestrogen such as isoflavones etc. provides new choosing
It selects.Isoflavones is to be present in a kind of bioactive substance with the effect of female hormone sample in soybean, altogether includes 12 kinds of changes
Object is closed, the 0.2%~0.4% of full soybean is accounted for about.Some researches show that isoflavones has a variety of pharmacological activity, swashs in addition to female
Plain sample effect, moreover it is possible to apparent pre- preventing bone rarefaction, anti-inflammatory, anti-oxidant, antitumor, the reduction a variety of estrogen-dependent type diseases of human body
The disease incidence of disease.Although the estrogenic activity of isoflavones is very faint, one estradiol of originality estrogen is living only in human body
Property one thousandth to a ten thousandth, but still can be used as exogenous estrogen supplement, generate estrogen-like action.The different Huang of soybean
Ketone treatment is still a kind of exogenous supplement therapy for substituting estrogen in essence, can be reduced to a certain extent and estrogen
The disease incidence of horizontal low caused related disease, but the synthesis constitution and aging phenomenon of women do not significantly improve.
Summary of the invention
Aiming at the problems existing in the prior art, the present invention provides a kind of soft capsules of Menopause anti-aging.It should
Soft capsule uses matrix of the granada seed oil as soft capsule, combines and glue is made with isoflavones and twocolor sealavander herb extract
It is intracapsular tolerant, the destruction of human free radical and inflammation can be resisted, anti-aging while can also effectively supplement women vim and vigour, make more
Term women symptom significantly mitigates, and skin smooth is compact flexible, radiant, and women is made to regain confidence.
The present invention also provides a kind of preparation methods of the soft capsule of Menopause anti-aging.
The invention adopts the following technical scheme:
A kind of soft capsule of Menopause anti-aging, is made of, the capsule 's content capsule 's content and capsule shells
Weight proportion are as follows: isoflavones extract powder: granada seed oil: twocolor sealavander herb extract: suspending agent: wetting agent=5:(85
~92): (5~8): (2~8): (1~7);The capsule shells are made of gelatin, plasticizer, colorant and water;The gelatin,
The weight ratio of plasticizer and water are as follows: 1:(0.3~0.7): 1;The colorant is by antholeucin and milk chocolate brown pigment group
At wherein antholeucin is the 0.05% of gelatin weight, and milk chocolate brown pigment is the 0.5% of gelatin weight.
Preferably, the twocolor sealavander herb extract is prepared using following methods: twocolor sealavander herb is cut into
Segment, thereto be added ten times of amount clear water, then using 80KHz ultrasonication 30min after addition papain into
Row enzymatic hydrolysis, hydrolysis temperature are 60 DEG C, and enzymolysis time is 1~2 hour;Filtrate is obtained by filtration after the completion of enzymatic hydrolysis, is concentrated under reduced pressure into 80
DEG C when relative density be 1.3 to obtain concentrate, vacuum freeze drying is at powder.
Preferably, the papain additional amount is 80U/g.
Preferably, the suspending agent is the one or more of beeswax, insect wax, soybean lecithin, glycerin monostearate.
Preferably, the wetting agent is one or more of tween, sapn, soybean lecithin.
Preferably, the plasticizer is one of sorbierite, propylene glycol, glycerol, low molecular poly.
A kind of preparation method of the soft capsule of Menopause anti-aging, it the following steps are included:
(1) preparation of content: quantitatively weighing granada seed oil, suspending agent, appropriate wetting agent, and heating makes suspending agent and wetting
Agent is melted in granada seed oil completely, is stirred and evenly mixed, and the isoflavones dry extract and two colors of 150 meshes were added after cooling
Herba limonii gmelinii extract is stirred for uniformly, grinding, stand, 45 DEG C of heat preservation bubble removings are spare;
(2) preparation of softgel shell: being set as 90 DEG C for vacuum mixer water-bath interlayer temperature in advance, quantitative distilled water be added,
Antholeucin and milk chocolate palm fibre colorant is then added, stirs evenly, when 85 DEG C of vacuum mixer Nei Wenduda, will be plasticized
Agent and gelatin are sequentially added into vacuum mixer, and stirring makes it be melt into uniform glue, after by vacuum mixer water-bath interlayer temperature
Degree is adjusted to (55 ± 5) DEG C, stands heat preservation 12 hours, glue is spare;
(3) common process pelleting, sizing are dried, wash ball, drying, pick up ball, pack up to product of the present invention.
Oil content is higher in pomegranate seed, and in granada seed oil fatty acid, unsaturated fatty acid accounts for 95.67%, saturated fatty acid
4.33% is only accounted for, wherein punicic acid accounts for the 81.62% of unsaturated fatty acid, and the chemical structure of punicic acid is cis- 9, trans- 11, cis-
13- octatecatrienoic acid, property is very active, is a kind of very unique effective antioxidant, can resist human body inflammation and oxygen
The destruction of free radical plays the role of anti-aging, prevention of arterial atherosis and slows down canceration process.Granada seed oil is one kind ten
Dividing and being beneficial to the natural ω -3 of human body is health-care oil, accounts for the 13%~23% of pomegranate seed, has good medical value and nutrition
Value.Polyphenol components make granada seed oil have the function of external human body breast cancer.Megranate Seed P.E has certain
Female hormone effect, is used clinically for the treatment of Woman climacteric disease, has to due to extracing the overturning of sclerotin caused by ovary
Certain inhibiting effect.Separately some researches show that, granada seed oil has certain inhibiting effect to mankind mastopathy cell and cutaneum carcinoma, and
And there are also certain preventive and therapeutic actions to cutaneum carcinoma.
Twocolor sealavander herb (Limonium bicolor) also known as broom grass, fly flower, spoon leaf grass, are Plumbaginaceaes
(Plumbaginaceae) one of Statice (Limonium Mill) plant, belongs to perennial herb.Statice is planted
Goods and materials source in the whole world there are about 300 kinds, wherein 17~18 kinds of North China, northeast, northwest and coastal regions for being distributed in China.Hebei
3 kinds, i.e. twocolor sealavander herb, Limonium aureum (Limoniumaureum) and limonium sinenseKuntze (Limonium are distributed in province
Sinense), wherein twocolor sealavander herb is most representative, has very high ornamental value, the ecological value, and in addition to this, two colors are mended
The medical value of blood grass also should not be underestimated, and herb can be used as medicine, and the sweet micro-puckery of nature and flavor is bitter.
The beneficial effects of the present invention are: the present invention is using granada seed oil as the matrix of soft capsule, in conjunction with isoflavones and
Twocolor sealavander herb extract, three's synergistic effect, not only acts as anti-oxidant, anti-aging, alleviates the effect of Menopause symptom,
Women vim and vigour can also be significantly supplemented, keep women radiant, complexion is full, and skin becomes smooth flexible, women synthesis
Matter be improved significantly, effect is better than the common soybean isoflavones capsules in market.Soybean is different in soft capsule prepared by the present invention
Flavones content is about 5%, i.e. 25mg/, recommends daily two, total content is higher than the common isoflavones flexible glue in market
Capsule.
Specific embodiment
The present invention is described in further detail combined with specific embodiments below.
Embodiment 1
A kind of soft capsule of Menopause anti-aging, is made of, the capsule 's content capsule 's content and capsule shells
Weight proportion are as follows: isoflavones extract powder: granada seed oil: twocolor sealavander herb extract: suspending agent: wetting agent=5:85:
5:2:1;The capsule shells are made of gelatin, plasticizer, colorant and water;The weight ratio of the gelatin, plasticizer and water are as follows:
1:(0.3~0.7): 1;The colorant is made of antholeucin and milk chocolate brown pigment, and wherein antholeucin is gelatin weight
The 0.05% of amount, milk chocolate brown pigment is the 0.5% of gelatin weight.Above-mentioned soft capsule the preparation method is as follows:
(1) preparation of content: quantitatively weighing granada seed oil, suspending agent, appropriate wetting agent, and heating makes suspending agent and wetting
Agent is melted in granada seed oil completely, is stirred and evenly mixed, and the isoflavones dry extract and two colors of 150 meshes were added after cooling
Herba limonii gmelinii extract is stirred for uniformly, grinding, stand, 45 DEG C of heat preservation bubble removings are spare;
(2) preparation of softgel shell: being set as 90 DEG C for vacuum mixer water-bath interlayer temperature in advance, quantitative distilled water be added,
Antholeucin and milk chocolate palm fibre colorant is then added, stirs evenly, when 85 DEG C of vacuum mixer Nei Wenduda, will be plasticized
Agent and gelatin are sequentially added into vacuum mixer, and stirring makes it be melt into uniform glue, after by vacuum mixer water-bath interlayer temperature
Degree is adjusted to (55 ± 5) DEG C, stands heat preservation 12 hours, glue is spare;
(3) common process pelleting, sizing are dried, wash ball, drying, pick up ball, pack up to product of the present invention.
Embodiment 2
A kind of soft capsule of Menopause anti-aging, is made of, the capsule 's content capsule 's content and capsule shells
Weight proportion are as follows: isoflavones extract powder: granada seed oil: twocolor sealavander herb extract: suspending agent: wetting agent=5:90:
8:6:5;The capsule shells are made of gelatin, plasticizer, colorant and water;The weight ratio of the gelatin, plasticizer and water are as follows:
1:(0.3~0.7): 1;The colorant is made of antholeucin and milk chocolate brown pigment, and wherein antholeucin is gelatin weight
The 0.05% of amount, milk chocolate brown pigment is the 0.5% of gelatin weight.
Above-mentioned soft capsule the preparation method is as follows:
(1) preparation of content: quantitatively weighing granada seed oil, suspending agent, appropriate wetting agent, and heating makes suspending agent and wetting
Agent is melted in granada seed oil completely, is stirred and evenly mixed, and the isoflavones dry extract and two colors of 150 meshes were added after cooling
Herba limonii gmelinii extract is stirred for uniformly, grinding, stand, 45 DEG C of heat preservation bubble removings are spare;
(2) preparation of softgel shell: being set as 90 DEG C for vacuum mixer water-bath interlayer temperature in advance, quantitative distilled water be added,
Antholeucin and milk chocolate palm fibre colorant is then added, stirs evenly, when 85 DEG C of vacuum mixer Nei Wenduda, will be plasticized
Agent and gelatin are sequentially added into vacuum mixer, and stirring makes it be melt into uniform glue, after by vacuum mixer water-bath interlayer temperature
Degree is adjusted to (55 ± 5) DEG C, stands heat preservation 12 hours, glue is spare;
(3) common process pelleting, sizing are dried, wash ball, drying, pick up ball, pack up to product of the present invention.
Embodiment 3
A kind of soft capsule of Menopause anti-aging, is made of, the capsule 's content capsule 's content and capsule shells
Weight proportion are as follows: isoflavones extract powder: granada seed oil: twocolor sealavander herb extract: suspending agent: wetting agent=5:92:
10:8:7;The capsule shells are made of gelatin, plasticizer, colorant and water;The weight ratio of the gelatin, plasticizer and water
Are as follows: 1:(0.3~0.7): 1;The colorant is made of antholeucin and milk chocolate brown pigment, and wherein antholeucin is gelatin
The 0.05% of weight, milk chocolate brown pigment are the 0.5% of gelatin weight.Above-mentioned soft capsule the preparation method is as follows:
(1) preparation of content: quantitatively weighing granada seed oil, suspending agent, appropriate wetting agent, and heating makes suspending agent and wetting
Agent is melted in granada seed oil completely, is stirred and evenly mixed, and the isoflavones dry extract and two colors of 150 meshes were added after cooling
Herba limonii gmelinii extract is stirred for uniformly, grinding, stand, 45 DEG C of heat preservation bubble removings are spare;
(2) preparation of softgel shell: being set as 90 DEG C for vacuum mixer water-bath interlayer temperature in advance, quantitative distilled water be added,
Antholeucin and milk chocolate palm fibre colorant is then added, stirs evenly, when 85 DEG C of vacuum mixer Nei Wenduda, will be plasticized
Agent and gelatin are sequentially added into vacuum mixer, and stirring makes it be melt into uniform glue, after by vacuum mixer water-bath interlayer temperature
Degree is adjusted to (55 ± 5) DEG C, stands heat preservation 12 hours, glue is spare;
(3) common process pelleting, sizing are dried, wash ball, drying, pick up ball, pack up to product of the present invention.
Comparative example 1
A kind of soybean isoflavone soft capsule, specific formula content and specific preparation method with embodiment 2, unlike: with
Equivalent soybean oil replaces the granada seed oil of equivalent.
Comparative example 2
A kind of soft capsule of Menopause anti-aging, formula composition and specific preparation method are different with embodiment 2
It is: without containing twocolor sealavander herb extract in capsule 's content.
Comparative example 3
A kind of soft capsule of Menopause anti-aging, formula composition and specific preparation method are different with embodiment 2
It is: only contains granada seed oil, suspending agent and wetting agent in capsule 's content.
The performance of the resulting Menopause Antiaging Soft Capusles of above-described embodiment is tested.
Product stability test: soft capsule prepared by embodiment 1-3 is kept in dark place at room temperature, respectively place 1,2,3,
6, it 12,18 months, checks on time, the appearance of every kind of sample must not change, and it is also qualified that effective component is examined, and be measured using ultraviolet method
Isoflavone content, sample size are also qualified.Specifically it is shown in Table 1.
1 stability test result of table
Disintegration time limited test: soft capsule prepared by embodiment 1-3 and comparative example 1-3 is according to " People's Republic of China's medicine
Allusion quotation " four 0921 disintegration time limit tests of general rule of version were tested 2015 years.Test result is as shown in table 2.
Table 2 disintegration time limited test result
Group | Time (min) |
Example 1 | 65 |
Example 2 | 67 |
Example 3 | 70 |
Comparison 1 | 65 |
Comparison 2 | 71 |
Comparison 3 | 66 |
As shown in above-mentioned Tables 1 and 2, Stability of Soft Capsules prepared by the present invention and disintegration time limited meet Chinese Pharmacopoeia
Related request, stability is all right, and the shelf-life can achieve 18 months.
Toxicological experiment: soft capsule prepared by 1-3 of the embodiment of the present invention is according to " health food is examined advises with assessment technique
Model " (version in 2003) carry out Toxicological evaluation, and test result shows: acute oral toxicity test LD50>
10.0kg.bw;Three genetic toxicity tests, mouse inbred strain, Salmonella reversion test result are feminine gender, have no production of the present invention
Product have pathogenic effects;Feeding trial terminates within 30 days, and experimental animal growing state is normal, and hematology adheres to, biochemical analysis, liver function
Inspection and histological indications and contrast ratio Non Apparent Abnormality.
Internal total antioxidation Effect study experiment
70 aged mouses are taken, animal is divided into 1-7 group by weight by half male and half female at random, and wherein 1-3 group is daily respectively
Gastric infusion is carried out according to the soft capsule of 10mg/kg embodiment 1-3 preparation, 4-6 group respectively corresponds pair of same dose daily
The drug stomach-filling of ratio 1, comparative example 2 and comparative example 3, the 7th group is blank control group, is filled daily by 10mg/kg distilled water
Stomach.Every group of mouse pulls out eyeball and takes blood and the execution that dislocates after stomach-filling 4 weeks, and separation serum fills immediately after 3500r/min is centrifuged 15 minutes
In eppendorf pipe, it is placed in -20 DEG C and saves for use.It is pushed away according to kit (building up Bioengineering Research Institute by Nanjing to provide)
The method of total antioxidant capacity (T-AOC) is measured in the measurement serum recommended.All data withIt indicates, using SAS
Statistical software carries out the variance analysis of completely random data to Antioxidant Indexes.Measurement result is as shown in table 3 below.
3 mice serum T-AOC measurement experiment result of table
Group | Number of animals (only) | T-AOC(U/ml) |
1 | 10 | 31.6±0.26** |
2 | 10 | 29.5±0.32** |
3 | 10 | 32.1±0.29** |
4 | 10 | 17.8±0.35 |
5 | 10 | 15.4±0.29 |
6 | 10 | 14.5±0.25 |
7 | 10 | 13.7±0.42 |
Note: * * is compared with blank control group, P < 0.01.
Its total economic value of soft gel products prepared by the present invention and blank control it can be seen from the data in upper table 3
Group is compared to the statistical significance with highly significant.
It enriches blood effect disquisition
Study the influence that product of the present invention causes mouse model of blood dificiency red blood cell, hemoglobin to acetylphenylhydrazine.Take mouse 90
Only, 9 groups, respectively blank control group, model group, embodiment 1-3 group and comparative example 1-3 group are randomly divided into, each group is to medicament
Amount is 10mg/kg, and blank control group and model group, which are given, waits capacity distilled water, per stomach-filling for 24 hours 1 time, successive administration 10d.It is positive
Control group is complex prescription glue mucilage (10mL/kg).In the Isosorbide-5-Nitrae of experiment, 7 days 2% acetylphenylhydrazine normal saline solutions of subcutaneous injection,
Initial dose is 200mg/kg, is halved for latter 2 times, and the 9th day of modeling can cause hemolytic model of blood dificiency.Start while modeling
Gastric infusion, each group mouse orbit is taken a blood sample after last dose 2h, observes the general features and red blood cell number and blood red egg of animal
White situation of change.
4 each group mouse red blood cell number of table, content of hemoglobin compare
Note: * * is compared with model group, P < 0.01.
After model group mouse subcutaneous injection acetylphenylhydrazine be can be seen that from the data in above-mentioned table 4, red blood cell number and blood red
Protein value is decreased obviously compared with blank control group mouse, and mouse general state is poor, and activity is reduced, apathetic, closes mesh, tail, ear
Color is pale, and coat is thick random, fluffy and matt, and weight reduces with diet and amount of drinking water and declined.And in the application present invention
Mouse red blood cell number and Hemoglobin Value are above model after the soft capsule of the Menopause anti-aging of embodiment 1-3 preparation
Group can achieve similar effect with compound ass-hide gelatin group, and mouse state is gradually restored normally, and hair color is glossy and fine and close, activity
Flexibly, ear, tail slightly reveal color.And comparative example 1-3 preparation soft capsule its either mouse red blood cell or Hemoglobin Value and
Model group relatively slightly increases, but effect is all not so good.This is because each component is synergistic in soft capsule of the invention, mend
Blood effect is better than the sum of the effect of three comparative examples.Soft capsule of the invention is oxidation resistant simultaneously in anti-aging, invigorating the blood
Effect is also very excellent, is a kind of health food that suitable climacteric women is edible.
Menopause Antiaging Soft Capusles human feeding trial of the present invention
Tested crowd: the age is chosen at women 400 of 45~65, there is menopause or few warp, cutis laxa tarnish, wrinkle
Line is obvious, color spot is constantly deepened, flush hectic fever, osteoporosis, dizziness headache, tinnitus, 3 kinds in the symptoms such as capricious and with
Upper symptom is diagnosed as menopausal syndrome women.4 groups are equally divided into, every group of 100 people, it is poor that each group age compares no conspicuousness
It is different.
Test-meal method: soft capsule prepared by the 1st group of edible embodiment of the present invention 2, daily 2.Edible pair respectively of 2-4 group
The soft capsule of ratio 1-3 preparation, daily 2.Result is observed after continuous test-meal 180 days.Concrete outcome is shown in Table 5.
Evaluation criterion:
Be obviously improved: cutis laxa is matt, wrinkle is obvious, color spot is constantly deepened, flush hectic fever, osteoporosis, dizziness
At least four kinds of basic disappearances or big portion disappear in the symptoms such as headache, tinnitus, capricious, and the state of mind is good;
Alleviate: cutis laxa is matt, wrinkle is obvious, color spot is constantly deepened, flush hectic fever, osteoporosis, dizziness headache,
At least two kinds of symptoms are substantially reduced in the symptoms such as tinnitus, capricious, and skin is gradually ruddy glossy, and the state of mind is preferable;
It is invalid: cutis laxa is matt, wrinkle is obvious, color spot is constantly deepened, flush hectic fever, osteoporosis, dizziness headache,
It has no significant change or aggravates in the symptoms such as tinnitus, capricious, the state of mind is poor.
5 test result of table statistics
Group | Case load | It is obviously improved example | Alleviate example | Invalid example | Total effective rate % |
1 | 100 | 56 | 42 | 2 | 98 |
2 | 100 | 33 | 39 | 28 | 72 |
3 | 100 | 33 | 35 | 32 | 68 |
4 | 100 | 5 | 20 | 75 | 25 |
It can be seen that Menopause Antiaging Soft Capusles prepared by the present invention from above-mentioned test result and alleviate climacteric disease
Shape effect is very excellent, and total effective rate reaches 98%, is better than comparative example experiment effect.And test-meal crowd long-term consumption of the present invention
Afterwards, without any side effects, and effect of enriching blood is also very significant, can keep having rosy cheeks for a long time glossy, skin is flexible
State, thus product of the present invention can make middle and aged women regain beautiful confidence, comprehensive constitution is obviously improved.
Claims (7)
1. a kind of soft capsule of Menopause anti-aging, is made of, which is characterized in that the glue capsule 's content and capsule shells
Intracapsular tolerant weight proportion are as follows: isoflavones extract powder: granada seed oil: twocolor sealavander herb extract: suspending agent: wetting agent
=5:(85~92): (5~8): (2~8): (1~7);The capsule shells are made of gelatin, plasticizer, colorant and water;Institute
State the weight ratio of glue, plasticizer and water clearly are as follows: 1:(0.3~0.7): 1;The colorant is by antholeucin and milk chocolate palm fibre
Pigment composition, wherein antholeucin is the 0.05% of gelatin weight, and milk chocolate brown pigment is the 0.5% of gelatin weight.
2. the soft capsule of Menopause anti-aging according to claim 1, which is characterized in that the twocolor sealavander herb mentions
It takes object to be prepared using following methods: twocolor sealavander herb is cut into segment, ten times of amount clear water are added thereto, then adopt
It is digested with after the ultrasonication 30min of 80KHz in addition papain, hydrolysis temperature is 60 DEG C, enzymolysis time 1
~2 hours;Filtrate is obtained by filtration after the completion of enzymatic hydrolysis, relative density obtains concentrate for 1.3 when being concentrated under reduced pressure into 80 DEG C, and vacuum is cold
Jelly is dried to powder.
3. the soft capsule of Menopause anti-aging according to claim 2, which is characterized in that papain additional amount
For 80 U/g.
4. the soft capsule of Menopause anti-aging according to claim 1, which is characterized in that the suspending agent is bee
The one or more of wax, insect wax, soybean lecithin, glycerin monostearate.
5. the soft capsule of Menopause anti-aging according to claim 1, which is characterized in that the wetting agent is to spit
One or more of temperature, sapn, soybean lecithin.
6. the soft capsule of Menopause anti-aging according to claim 1, which is characterized in that the plasticizer is sorb
One of alcohol, propylene glycol, glycerol, low molecular poly.
7. a kind of preparation method of the soft capsule of Menopause anti-aging described in claim 1, which is characterized in that it includes
Following steps:
(1) preparation of content: quantitatively weighing granada seed oil, suspending agent, appropriate wetting agent, and heating keeps suspending agent and wetting agent complete
It is melted in granada seed oil, stirs and evenly mixs entirely, the isoflavones dry extract of 150 meshes was added after cooling and two colors are enriched blood
Careless extract is stirred for uniformly, grinding, stand, 45 DEG C of heat preservation bubble removings are spare;
(2) preparation of softgel shell: vacuum mixer water-bath interlayer temperature is set as 90 DEG C in advance, quantitative distilled water is added, then
Antholeucin and milk chocolate palm fibre colorant is added, stirs evenly, when 85 DEG C of vacuum mixer Nei Wenduda,
Plasticizer and gelatin are sequentially added into vacuum mixer, stirring makes it be melt into uniform glue, after by vacuum mixer
Water-bath interlayer temperature is adjusted to (55 ± 5) DEG C, stands heat preservation 12 hours, glue is spare;
(3) common process pelleting, sizing are dried, wash ball, drying, pick up ball, pack up to product of the present invention.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910650635.9A CN110237117A (en) | 2019-07-18 | 2019-07-18 | A kind of soft capsule and preparation method thereof of Menopause anti-aging |
PCT/CN2020/094141 WO2021008265A1 (en) | 2019-07-18 | 2020-06-03 | Anti-aging soft capsule for menopausal women and preparation method therefor |
LU102669A LU102669B1 (en) | 2019-07-18 | 2020-06-03 | Anti-aging soft capsule for menopausal women and preparation method therefor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910650635.9A CN110237117A (en) | 2019-07-18 | 2019-07-18 | A kind of soft capsule and preparation method thereof of Menopause anti-aging |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110237117A true CN110237117A (en) | 2019-09-17 |
Family
ID=67892833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910650635.9A Pending CN110237117A (en) | 2019-07-18 | 2019-07-18 | A kind of soft capsule and preparation method thereof of Menopause anti-aging |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN110237117A (en) |
LU (1) | LU102669B1 (en) |
WO (1) | WO2021008265A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021008265A1 (en) * | 2019-07-18 | 2021-01-21 | 枣庄学院 | Anti-aging soft capsule for menopausal women and preparation method therefor |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114832030A (en) * | 2022-04-22 | 2022-08-02 | 沈阳市泰阳中医中药研究所 | Chinese medicinal capsule with anti-tumor and anti-aging effects, and its preparation method and application |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1259046C (en) * | 2003-06-26 | 2006-06-14 | 新疆特丰药业股份有限公司 | Soyisoflavone soft capsule and its preparation technology |
CN1785218A (en) * | 2005-11-22 | 2006-06-14 | 华中科技大学 | Extractive of pomegranate seeds, prepn. method and application in preparing medicine thereof |
CN101810336A (en) * | 2010-04-30 | 2010-08-25 | 广东仙乐制药有限公司 | Chewable soft capsules and method for preparing same |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106138122B (en) * | 2015-04-03 | 2020-08-25 | 伽蓝(集团)股份有限公司 | Limonium sinense (DC.) kuntze extract and preparation method and application thereof |
CN110237117A (en) * | 2019-07-18 | 2019-09-17 | 枣庄学院 | A kind of soft capsule and preparation method thereof of Menopause anti-aging |
-
2019
- 2019-07-18 CN CN201910650635.9A patent/CN110237117A/en active Pending
-
2020
- 2020-06-03 LU LU102669A patent/LU102669B1/en active IP Right Grant
- 2020-06-03 WO PCT/CN2020/094141 patent/WO2021008265A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1259046C (en) * | 2003-06-26 | 2006-06-14 | 新疆特丰药业股份有限公司 | Soyisoflavone soft capsule and its preparation technology |
CN1785218A (en) * | 2005-11-22 | 2006-06-14 | 华中科技大学 | Extractive of pomegranate seeds, prepn. method and application in preparing medicine thereof |
CN101810336A (en) * | 2010-04-30 | 2010-08-25 | 广东仙乐制药有限公司 | Chewable soft capsules and method for preparing same |
Non-Patent Citations (4)
Title |
---|
徐润,徐时主编: "《应用功能性食物延缓衰老》", 31 August 2010, 人民军医出版社 * |
王云云主编: "《药物制剂技术》", 31 August 2016, 重庆大学出版社 * |
秦改花主编: "《石榴优质高效栽培新技术》", 30 September 2015, 安徽科学技术出版社 * |
高文远著: "《中药生物工程》", 31 January 2014, 上海科学技术出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021008265A1 (en) * | 2019-07-18 | 2021-01-21 | 枣庄学院 | Anti-aging soft capsule for menopausal women and preparation method therefor |
Also Published As
Publication number | Publication date |
---|---|
WO2021008265A1 (en) | 2021-01-21 |
LU102669B1 (en) | 2021-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101695376B (en) | Health-care food for preventing diabetes | |
CN105249326A (en) | Fermented fruit and vegetable composition containing probiotics and traditional Chinese medicine extract and preparation method of fermented fruit and vegetable composition | |
CN103501800B (en) | Beautiful-skin-promoting agent and use thereof | |
CN102172269B (en) | Hidegelatin fabricated food with beautification function | |
CN103141709A (en) | Carp feed and preparation method thereof | |
CN102406860A (en) | Composition for preventing and treating diabetes, and preparation method and use thereof | |
CN110237104A (en) | It is suitable for the health-oriented products composition of adult female, old man and sub-health state crowd | |
CN101253903B (en) | Health food with fat-reducing function and its preparation | |
CN101284122A (en) | Soft capsules for resisting the climate sickness | |
CN101579120A (en) | Nutritional food with weight-losing function and preparation method thereof | |
CN106551398A (en) | A kind of anti-aging cream taste and preparation method thereof | |
CN109090617A (en) | It is a kind of to have effects that the formulation product of qi-supplementing, blood-engendering | |
CN107373672A (en) | A kind of irregular menstruation women tailored version clinical nutrition formula and preparation method thereof | |
CN104352552A (en) | Food, health care product or medicine composition | |
CN110237117A (en) | A kind of soft capsule and preparation method thereof of Menopause anti-aging | |
CN101152239A (en) | Technique of preparing drone pupa freeze-dried powder medicinal granules and capsule | |
CN110403200A (en) | Nostoc composition and its application in alleviation eye strain, improvement eye maculopathy | |
CN102246956A (en) | Healthcare food containing pollen pini and preparation method thereof | |
CN103445116A (en) | Healthcare radix puerariae nutrition powder with blood fat regulating effect | |
CN102090637A (en) | Collagen-containing compound nutritious powder | |
CN101816426B (en) | Mixture of pine pollen/flaxseed powder/giant salamander powder and preparation method thereof | |
CN103238757A (en) | Compound feed containing fermented cottonseed meal for chicken for eggs and preparation method thereof | |
CN103920140B (en) | A kind of people is with blood sugar lowering Weight-reducing and lipid-lowering compound preparation | |
CN110638038A (en) | Medical formula nutritional meal replacement powder for controlling hyperglycemia and preparation method thereof | |
CN102302114A (en) | Pollen-containing health-care food and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190917 |
|
RJ01 | Rejection of invention patent application after publication |